Helix BioPharma Corp. (HBPCF)
OTCMKTS · Delayed Price · Currency is USD
1.734
+1.134 (189.00%)
At close: Oct 22, 2025

Helix BioPharma Ratios and Metrics

Millions USD. Fiscal year is Aug - Jul.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2016 - 2020
Period Ending
Oct '25 Jul '25 Jul '24 Jul '23 Jul '22 Jul '21 2016 - 2020
Market Capitalization
1295741322594
Upgrade
Market Cap Growth
215.89%40.48%27.81%25.38%-72.89%75.26%
Upgrade
Enterprise Value
1295740312692
Upgrade
Last Close Price
1.730.600.830.720.773.58
Upgrade
PB Ratio
11.455.09-626.39-49.71102.32-84.09
Upgrade
P/TBV Ratio
----102.32-
Upgrade
Debt / Equity Ratio
0.020.02--7.74-2.59
Upgrade
Quick Ratio
0.060.060.720.461.031.01
Upgrade
Current Ratio
0.130.130.920.531.081.04
Upgrade
Return on Equity (ROE)
-67.18%-67.18%----1205.79%
Upgrade
Return on Assets (ROA)
-33.25%-33.25%-458.65%-166.12%-96.84%-127.23%
Upgrade
Return on Capital (ROIC)
-42.61%-42.61%--407.18%-150.82%-212.98%
Upgrade
Return on Capital Employed (ROCE)
-34.60%-34.60%10265.60%748.60%-1887.50%-4780.60%
Upgrade
Earnings Yield
-2.92%-6.56%-16.43%-14.97%-20.11%-6.86%
Upgrade
FCF Yield
-2.15%-4.83%-9.28%-13.18%-19.94%-7.94%
Upgrade
Buyback Yield / Dilution
-25.29%-25.29%-15.11%-29.26%-8.41%-7.97%
Upgrade
Updated Jul 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.